ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-1-1 |
rdf:type |
rdfs:Resource |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-1-1 |
rdf:type |
owl:Thing |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-1-1 |
rdf:type |
ripe:IntegrityAssessmentHypothesisIntegrity assessment hypothesis |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-1-1 |
rdf:type |
tido:Hypothesis |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-1-1 |
prov:wasAttributedTo |
ripekg:automated-agent/inspect-ai/1.0.0INSPECT-AI 1.0.0 |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-1-1 |
prov:wasAttributedTo |
ripekg:automated-agent/inspect-ai/1.0.0INSPECT-AI |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-1-1 |
prov:wasGeneratedBy |
ripekg:evaluation/RIPEA62FEC5B159F50CEC |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-1-1 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-1-1 |
ripe:resultOutcome |
no |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-1-1 |
tido:answers |
ripekg:integrity-assessment-question/retraction-status/1.0.01.1. Does the study have an associated retraction? |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-1-1 |
tido:answers |
ripekg:integrity-assessment-question/retraction-status/1.0.0retraction status |
ripekg:publication-details/RIPEA62FEC5B159F50CECOnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-1-1 |